Liver-targeted prodrug of tafenoquine enhances malaria treatment

Summary: A new study in Scientific Advances introduces a liver-targeted polymeric prodrug of tafenoquine (TQ) that could enhance malaria treatment. With nearly 250 million malaria cases and over 600,000 deaths in 2021, the need for radical cure drugs is critical. The prodrug, administered subcutaneously, shows promise in reducing hemolytic anemia risk and improving parasite elimination. This development could advance mass eradication efforts and address the urgent need for effective malaria therapies.

Full article